Skip to main content
Lupin Ltd logo

Lupin Ltd — Investor Relations & Filings

Ticker · LUPIN ISIN · INE326A01037 LEI · 335800HHXTESDEE2FC65 BSE.NS Manufacturing
Open in API
Filings indexed 3,166 across all filing types
Latest filing 2025-10-30 Regulatory Filings
Country IN India
Listing BSE.NS LUPIN

About Lupin Ltd

https://www.lupin.com/

Lupin Ltd is a global pharmaceutical organization specializing in the development, manufacturing, and marketing of a comprehensive range of generic and branded formulations, biotechnology products, and active pharmaceutical ingredients. The company holds a significant market position in therapeutic segments such as cardiovascular, diabetology, asthma, pediatrics, gastrointestinal, anti-infectives, and non-steroidal anti-inflammatory drugs. It is notably recognized for its leadership in the anti-tuberculosis medication sector. With a strong emphasis on research and development, Lupin focuses on complex generics, specialty medicines, and biosimilars. The company operates advanced manufacturing facilities and maintains a substantial commercial presence across major global markets, including North America, Europe, and the Asia-Pacific region, delivering affordable and high-quality healthcare solutions.

Recent filings

Filing Released Lang Actions
Lupin Digital Health Launches VITALYFE. .
Regulatory Filings
2025-10-30 English
Inauguration of Lupin''s New Corporate Offices in Bridgewater, New Jersey.
Regulatory Filings
2025-10-28 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release announcing the inauguration of Lupin Limited's new corporate offices in Bridgewater, New Jersey. It is addressed to stock exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which governs disclosure of material events. The content focuses on the event of opening new offices, statements from executives and local officials, and the company's expansion plans. There are no financial statements, earnings data, management discussion, or regulatory filings related to financial performance. The document is not a report, but an announcement of a corporate event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-10-28 English
Intimation regarding allotment of 4312 shares under ESOPs.
Regulatory Filings
2025-10-28 English
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 100% confidence The document is a notification to stock exchanges about the allotment of shares under the company's Employee Stock Option Plan (ESOP). It mentions the allotment of fully paid-up equity shares upon exercising vested options, resulting in an increase in the company's paid-up share capital. The document is short (1620 characters) and serves as an announcement of a capital change rather than a detailed financial report or analysis. It does not contain financial statements or management discussion. Therefore, it fits the category of Share Issue/Capital Change (SHA).
2025-10-28 English
Schedule of Earnings Call for Unaudited Financial Results of Q2 FY26.
Regulatory Filings
2025-10-27 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.